

Application No. 10/780,905
Paper Filed: April 20, 2005
Attorney Docket No. 4303-040164

Handwritten signature/initials

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/780,905
Applicants : Daniel Paris et al.
Filed : February 18, 2004
Title : ANTI-ANGIOGENIC AND ANTI-TUMORAL PROPERTIES OF
BETA AND GAMMA SECRETASE INHIBITORS
Group Art Unit : 1654
Examiner : Marcela M. Cordero Garcia
Confirmation Number: 7571
Customer Number : 28289

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the requirements of 37 CFR §§ 1.56, 1.97, and 1.98, the Applicants hereby submit this Information Disclosure Statement together with a completed Form PTO/SB/08A and one copy of the references, other than the United States patents, listed thereon.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on April 20, 2005.	
Helen Gerace	
(Name of Person Mailing Paper)	
<i>Handwritten Signature</i>	April 20, 2005
Signature	Date

04/26/2005 HMARZI1 00000005 10780905

01 FC:1806

180.00 UP


Application No. 10/780,905
Paper Dated: April 20, 2005
Attorney Docket No. 4303-040164


The references identified on Form PTO/SB/08A were cited and discussed in the specification of the application.

Pursuant to 37 C.F.R. §§1.97(c) and 1.17(p) a fee of \$180.00 is due for the submission of this Information Disclosure Statement, as it is being submitted after the mailing date of a first Office Action on the merits and before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311. The Commissioner for Patents is hereby authorized to charge any fees which may be required to Deposit Account No. 23-0650. One (1) original and two (2) copies of this Information Disclosure Statement are enclosed.

Respectfully submitted,

WEBB ZIESENHEIM LOGSDON
ORKIN & HANSON, P.C.

By 
Gwen R. Wood
Registration No. 51,027
Attorney for Applicants
700 Koppers Building
436 Seventh Avenue
Pittsburgh, PA 15219-1818
Telephone: 412-471-8815
Facsimile: 412-471-4094
E-mail: webblaw@webblaw.com



Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2001. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/780,905
Filing Date	February 18, 2004
First Named Inventor	Daniel Paris
Group Art Unit	1654
Examiner Name	Marcela M. Cordero Garcia
Attorney Docket Number	4303-040164

Sheet 1 of 1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cite and/or country where published.	T ²
		CARMELET, Peter, Mechanisms of angiogenesis and arteriogenesis, Nature Medicine, Vol. 6, No. 3, March 2000, pgs. 389-395.	
		VASSAR, Robert et al., β -Secretase Cleavage of Alzheimer's Amyloid Precursor..., Science Vol. 286, October 22, 1999, pgs. 735-741.	
		Hussain, Ishrut, Identification of a Novel Aspartic Protease (Asp 2) as β -Secretase, Molecular and Cellular Neuroscience 14, 419-427 (1999).	
		YU, Gang et al., Journal of Biological Chemistry, Vol. 273 No. 26, Issue of June 26, pp 16470-16475, 1998.	
		CAPELL, Anja et al., The Proteolytic Fragments of the Alzheimer's Disease-associated..., Journal of Biological Chemistry, Vol. 273, No. 6, Issue of February 6, pp. 3205-3211, 1998.	
		WOLFE, Michael S., The Role of Presenilins in γ -Secretase Activity, The Journal of Biological Chemistry, Vol. 276, No. 8, Issue of February 23, pp. 5413-5416, 2001.	
		De STROOPER, Bart et al., A presenilin-1-dependent γ -secretase-like protease..., Nature, Vol. 398, April 8, 1999, pgs. 518-522.	
		ARTAVANIS-TSAKONAS, Spyros et al., Notch Signaling: Cell Fate Control and Signal Integration in Development, Science Magazine, April 30, 1999, Vol. 284, pgs. 770-776.	
		BROU, Christel, A Novel Proteolytic Cleavage Involved in Notch Signaling: The Role of the Disintegrin-Metalloprotease TACE, Molecular Cell, Vol. 5, February 2000, pgs. 207-216.	
		GREENWALD, Iva, LIN-12/Notch signaling: lessons from worms and flies, Genes & Development, 12, pgs. 1751-1762.	
		CAO, Xinwei et al., A Transcriptionally Active Complex of APP with Fe65 and Histone Acetyltransferase Tip60, Science Magazine, Vol. 293, July 6, 2001, pgs. 115-120.	
		GUO, Qing et al., Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid β -peptide, Neurochemistry, Vol. 8 No. 1, December 20, 1996, pgs. 379-383.	
		LEISSRING, Malcolm A. et al., Capacitative Calcium Entry Deficits and Elevated Luminal Calcium Content in Mutant Presenilin-1 Knockin Mice, The Journal of Cell Biology, Vol. 149, No. 4, May 15, 2000, pgs. 793-797.	
		ZHONG, Tao P. et al., Gridlock signaling pathway fashions the first embryonic artery, Nature, Vol. 414, November 8, 2001, pgs. 216-220.	
		HERREMAN, An et al, Presenilin 2 deficiency causes a mild pulmonary phenotype..., PNAS, 12, 1999, pgs. 11872-11877.	
		SHEN Jie, Skeletal and CNS Defects in Presenilin-1-Deficient Mice, Cell, Vol. 89, May 16, 1997, pgs. 629-639.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

{W0179562.1}



PTO/SB/21 (04-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/780,905	
	Filing Date	February 18, 2004	
	First Named Inventor	Daniel Paris	
	Art Unit	1654	
	Examiner Name	Marcela M. Cordero Garcia	
Total Number of Pages in This Submission	too many to list	Attorney Docket Number	4303-040164

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Fee Attached <input type="checkbox"/> Preliminary Amendment <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawings (1 sheet attached to Amendment.) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition for Extension of Time <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below) PTO/SB/08A (1 p. with references)
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Gwen R. Wood, Ph.D.	Registration No. 51,027
Signature	<i>Gwen R. Wood</i>	
Date	April 21, 2005	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Helen Gerace		
Signature	<i>Helen Gerace</i>	Date	April 21, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

{W0179552.1}

APR 25 2005

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.

Consolidated Appropriations Act, 2005 (H.R. 4818)

FEE TRANSMITTAL

For FY 2005

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$180.00)

Complete if Known

Application Number	10/780,905
Filing Date	February 18, 2004
First Named Inventor	Daniel Paris
Examiner Name	Marcela M. Cordero Garcia
Art Unit	1654
Attorney Docket No.	4303-040164

METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____

☒ Deposit Account Deposit Account Number: 23-0650 Deposit Account Name: _____

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☐ Charge fee(s) indicated below

☐ Charge fee(s) indicated below, except for the filing fee

☒ Charge any additional fee(s) or underpayments of fee(s)
Under 37 CFR 1.16 and 1.17

☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION

1. BASIC FILING, SEARCH, AND EXAMINATION FEES

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Small Entity	Fee (\$)	Small Entity	Fee (\$)	Small Entity	Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description

Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent

Small Entity
Fee (\$)

Fee (\$)

Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent

200 100

Multiple dependent claims

360 180

Total Claims Extra Claims Fee (\$) Fee Paid (\$)
49 - 49 or HP = 0 x = 0

HP = highest number of total claims paid for, if greater than 20

Multiple Dependent Claims

Fee (\$) Fee Paid (\$)

0

Indep. Claims Extra Claims Fee (\$) Fee Paid (\$)
3 - 3 or HP = 0 x = 0

HP = highest number of independent claims paid for, if greater than 3

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$) Fee Paid (\$)
- 100 = / 50 = (round up to a whole number) x =

4. OTHER FEE(S)


Non-English Specification, \$130 fee (no small entity discount)

Other: Information Disclosure Statement

Fee Paid (\$)

\$180.00

SUBMITTED BY

Signature		Registration No. (Attorney/Agent)	51,027	Telephone	412-471-8815
Name (Print/Type)	Gwen R. Wood, Ph.D.	Date	April 21, 2005		

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.